Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 15/3/2021
SIETES contiene 93212 citas

 
 
 1 a 20 de 122 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
3. Cita con resumen
Anónimo. Délamanid et tuberculose pulmonaire multirésistante. Prescrire 2017;37:10. [Ref.ID 101359]
4. Cita con resumen
Anónimo. Ibalizumab shows promising results treating multi-drug-resistant HIV. DIA Daily 2016:4. [Ref.ID 100869]
5. Cita con resumen
Diacon AH, van der Merwe L, Barnard M, von Groote-Bidlingmaier F, Lange C, García-Basteiro AL, Sevene E, Ballell L, Barros-Aguirre D. ß-lactams against tuberculosis — New trick for an old dog?. N Engl J Med 2016;375:393-4. [Ref.ID 100492]
6. Cita con resumen
Alpern JD, Song J, Stauffer WM. Essential medicines in the United States - Why access is diminishing. N Engl J Med 2016;374:1904-7. [Ref.ID 100324]
7. Cita con resumen
Kesselheim AS, Laggs LR, Sarpatwari A. Experience with the priority review voucher program for drug development. JAMA 2015;314:27 de octubre. [Ref.ID 99526]
9.Enlace a cita original
Goulooze SC, Cohen AF, Rissmann R. Bedaquiline. Br J Clin Pharmacol 2015;80:182-4. [Ref.ID 99475]
10. Cita con resumen
Anónimo. Bedaquiline for multidrug-resistant tuberculosis. Drug Ther Bull 2014;52:129-32. [Ref.ID 98318]
11. Cita con resumen
Anónimo. Acide para-aminosalicylique. Prescrire 2014;34:340-1. [Ref.ID 97559]
12. Cita con resumen
Pietersen E, Ignatius E, Streicher EM, Mastrapa B, Padanilam X, Pooran A, Badri M, Lesosky M, van Helden P, Sirgel FA, Warren R, Dheda K. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet 2014;383:1230-9. [Ref.ID 97376]
13. Cita con resumen
Avorn J. Approval of a tuberculosis drug based on a paradoxical surrogate measure. JAMA 2013;309:1349-50. [Ref.ID 95234]
14. Cita con resumen
Anónimo. FDA approves MDR-TB treatment. DIA Daily 2013:1. [Ref.ID 94616]
15.Tiene citas relacionadas
Chaisson RE, Nuermberger EL. Confronting multidrug-resistant tuberculosis. N Engl J Med 2012;366:2223-4. [Ref.ID 93175]
16.Tiene citas relacionadas Cita con resumen
Gier MT, Skripoconoka V, Sánchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, Suh GY, Danilovits M, Ogata H, Kurve A, Chang J, Suzuki K, Tupasi T, Koh W-J, Seaworth B, Geiter LJ, Wells CD. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012;366:2151-60. [Ref.ID 93171]
17.Enlace a cita original
Ahuja SD, Ashkin D, Avendaño M, Banerjee R, Bauer M, Bayona JN, Becerra MC, Benedetti A, Burgos M, Centis R, Chan ED, Chiang C-Y, Cox H, D'Ambrosio L, DeRiemer K, Dung NH, Enarson D, Falzon D, Flanagan K, Flood J, Garcia-Garcia ML, Gandhi N, Granich RM, Hollm-Delgado MG, Holtz TH, Iseman M, Jarlsberg LG, Keshavjee S, Kim H-R, Koh W-J, Lancaster J, Lange C, de Lange WCM, Leimane V, Leung CC, Li J, Menzies D, Migliori GB, Mishustin SP, Mitnick CD, Narita M, O'Riordan P, Pai M, Palmero D, Park SK, Pasvol G, Peña J, Pérez-Guzmán C, Quelapio MID, Ponce-de-León A, Riekstina V, Robert J, Royce S, Schaaf HS, Seung KJ, Shah L, Shim TS, Shin SS, Shiraishi Y, Sifuentes-Osornio J, Sotgiu G, Strand MJ, Tabarsi P, Tupasi TE, van Altena R, VAn der Walt M, van der Werf TS, Vargas MH, Viiklepp P, Westenhouse J, Yew WW, Yim J-J, on behalf of the Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLOS Medicine 2012;9:1-9. [Ref.ID 92933]
18. Cita con resumen
Mosynski P. Care for drug resistant TB fails in a quarter of cases in Europe. BMJ 2011;343:559. [Ref.ID 91469]
19.Tiene citas relacionadas
Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, Gler MT, Blakemore R, Worodria W, Gray C, Huang L, Caceres T, Mehdiyev R, Raymond L, Whitelaw A, Sagadevan K, Alexander H, Albert H, Cobelens F, Cox H, Alland D, Perkins MD. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011;377:1495-505. [Ref.ID 90682]
20.Tiene citas relacionadas Cita con resumen
Kranzer K. Improving tuberculosis diagnostics and treatment. Lancet 2011;377:1467-8. [Ref.ID 90673]
Seleccionar todas
 
 1 a 20 de 122 siguiente >>